New Susceptibility Breakpoints for First-Line Antituberculosis Drugs Based on Antimicrobial Pharmacokinetic/Pharmacodynamic Science and Population Pharmacokinetic VariabilityGUMBO, Tawanda.Antimicrobial agents and chemotherapy. 2010, Vol 54, Num 4, pp 1484-1491, issn 0066-4804, 8 p.Article

A Meta-Analysis of Self-Administered vs Directly Observed Therapy Effect on Microbiologic Failure, Relapse, and Acquired Drug Resistance in Tuberculosis PatientsPASIPANODYA, Jotam G; GUMBO, Tawanda.Clinical infectious diseases. 2013, Vol 57, Num 1, pp 21-31, issn 1058-4838, 11 p.Article

An Oracle: Antituberculosis Pharmacokinetics-Pharmacodynamics, Clinical Correlation, and Clinical Trial Simulations To Predict the FuturePASIPANODYA, Jotam; GUMBO, Tawanda.Antimicrobial agents and chemotherapy. 2011, Vol 55, Num 1, pp 24-34, issn 0066-4804, 11 p.Article

Clinical and Toxicodynamic Evidence that High-Dose Pyrazinamide Is Not More Hepatotoxic than the Low Doses Currently UsedPASIPANODYA, Jotam G; GUMBO, Tawanda.Antimicrobial agents and chemotherapy. 2010, Vol 54, Num 7, pp 2847-2854, issn 0066-4804, 8 p.Article

Fractal Geometry and the Pharmacometrics of Micafungin in Overweight, Obese, and Extremely Obese PeopleHALL, Ronald G; SWANCUTT, Mark A; GUMBO, Tawanda et al.Antimicrobial agents and chemotherapy. 2011, Vol 55, Num 11, pp 5107-5112, issn 0066-4804, 6 p.Article

Meta-Analysis of Clinical Studies Supports the Pharmacokinetic Variability Hypothesis for Acquired Drug Resistance and Failure of Antituberculosis TherapyPASIPANODYA, Jotam G; SRIVASTAVA, Shashikant; GUMBO, Tawanda et al.Clinical infectious diseases. 2012, Vol 55, Num 2, pp 169-177, issn 1058-4838, 9 p.Article

In Vitro and In Vivo Modeling of Tuberculosis Drugs and its Impact on Optimization of Doses and RegimensSRIVASTAVA, Shashikant; GUMBO, Tawanda.Current pharmaceutical design (Print). 2011, Vol 17, Num 27, pp 2881-2888, issn 1381-6128, 8 p.Article

Nattrassia mangiferae endophthalmitisGUMBO, Tawanda; MKANGANWI, Ndodini; ROBERTSON, Valerie J et al.Mycoses. 2002, Vol 45, Num 3-4, pp 118-119, issn 0933-7407Article

Pharmacokinetic Mismatch Does Not Lead to Emergence of Isoniazid-or Rifampin-Resistant Mycobacterium tuberculosis. but to Better Antimicrobial Effect: a New Paradigm for Antituberculosis Drug SchedulingSRIVASTAVA, Shashikant; SHERMAN, Carleton; MEEK, Claudia et al.Antimicrobial agents and chemotherapy. 2011, Vol 55, Num 11, pp 5085-5089, issn 0066-4804, 5 p.Article

Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistanceGUMBO, Tawanda; LOUIE, Arnold; DEZIEL, Mark R et al.Antimicrobial agents and chemotherapy. 2005, Vol 49, Num 8, pp 3178-3181, issn 0066-4804, 4 p.Article

Ethambutol Optimal Clinical Dose and Susceptibility Breakpoint Identification by Use of a Novel Pharmacokinetic-Pharmacodynamic Model of Disseminated Intracellular Mycobacterium aviumDESHPANDE, Devyani; SRIVASTAVA, Shashikant; MEEK, Claudia et al.Antimicrobial agents and chemotherapy. 2010, Vol 54, Num 5, pp 1728-1733, issn 0066-4804, 6 p.Article

The crisis of resistance : Identifying drug exposures to suppress amplification of resistant mutant subpopulationsDRUSANO, G. L; LOUIE, Arnold; DEZIEL, Mark et al.Clinical infectious diseases. 2006, Vol 42, Num 4, pp 525-532, issn 1058-4838, 8 p.Article

Moxifloxacin Pharmacokinetics/Pharmacodynamics and Optimal Dose and Susceptibility Breakpoint Identification for Treatment of Disseminated Mycobacterium avium InfectionDESHPANDE, Devyani; SRIVASTAVA, Shashikant; MEEK, Claudia et al.Antimicrobial agents and chemotherapy. 2010, Vol 54, Num 6, pp 2534-2539, issn 0066-4804, 6 p.Article

Efflux-Pump-Derived Multiple Drug Resistance to Ethambutol Monotherapy in Mycobacterium tuberculosis and the Pharmacokinetics and Pharmacodynamics of EthambutolSRIVASTAVA, Shashikant; MUSUKA, Sandirai; SHERMAN, Carleton et al.The Journal of infectious diseases. 2010, Vol 201, Num 8, pp 1225-1231, issn 0022-1899, 7 p.Article

Pharmacokinetics-Pharmacodynamics of Pyrazinamide in a Novel In Vitro Model of Tuberculosis for Sterilizing Effect: a Paradigm for Faster Assessment of New Antituberculosis DrugsGUMBO, Tawanda; SIYAMBALAPITIYAGE DONA, Chandima S. W; MEEK, Claudia et al.Antimicrobial agents and chemotherapy. 2009, Vol 53, Num 8, pp 3197-3204, issn 0066-4804, 8 p.Article

Cryptococcus myelitis : Atypical presentation of a common infectionGUMBO, Tawanda; HAKIM, James G; MIELKE, Jens et al.Clinical infectious diseases. 2001, Vol 32, Num 8, pp 1235-1236, issn 1058-4838Article

Recurrent pneumonia from an ileobronchial fistula complicating Crohn's diseaseGUMBO, Tawanda; RICE, Thomas W; MAWHORTER, Steven et al.Journal of clinical gastroenterology. 2001, Vol 32, Num 4, pp 365-367, issn 0192-0790Conference Paper

Pegylated Interferon Fractal Pharmacokinetics: Individualized Dosing for Hepatitis C Virus InfectionJAIN, Mamta K; PASIPANODYA, Jotam G; ALDER, Lara et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 3, pp 1115-1120, issn 0066-4804, 6 p.Article

In Silico Children and the Glass Mouse Model: Clinical Trial Simulations To Identify and Individualize Optimal Isoniazid Doses in Children with TuberculosisJEENA, Prakash M; BISHAI, William R; PASIPANODYA, Jotam G et al.Antimicrobial agents and chemotherapy. 2011, Vol 55, Num 2, pp 539-545, issn 0066-4804, 7 p.Article

Cryptococcus neoformans meningoencephalitis in African children with acquired immunodeficiency syndromeGUMBO, Tawanda; KADZIRANGE, Gerard; MIELKE, Jens et al.The Pediatric infectious disease journal. 2002, Vol 21, Num 1, pp 54-56, issn 0891-3668Article

Late complications of Candida (Torulopsis) glabrata fungemia: Description of a phenomenonGUMBO, Tawanda; CHEMALY, Roy F; ISADA, Carlos M et al.Scandinavian journal of infectious diseases. 2002, Vol 34, Num 11, pp 817-818, issn 0036-5548, 2 p.Article

Serum Drug Concentrations Predictive of Pulmonary Tuberculosis OutcomesPASIPANODYA, Jotam G; MCLLLERON, Helen; BURGER, André et al.The Journal of infectious diseases. 2013, Vol 208, Num 9, pp 1464-1473, issn 0022-1899, 10 p.Article

Ethambutol Pharmacokinetic Variability Is Linked to Body Mass in Overweight, Obese, and Extremely Obese PeopleHALL, Ronald G; SWANCUTT, Mark A; MEEK, Claudia et al.Antimicrobial agents and chemotherapy. 2012, Vol 56, Num 3, pp 1502-1507, issn 0066-4804, 6 p.Article

Clinicopathological features of cutaneous histoplasmosis in human immunodeficiency virus-infected patients in ZimbabweGUMBO, Tawanda; JUST-NÜBLING, Gudrun; ROBERTSON, Valerie et al.Transactions of the Royal Society of Tropical Medicine and Hygiene. 2001, Vol 95, Num 6, pp 635-636, issn 0035-9203Article

Weight Drives Caspofungin Pharmacokinetic Variability in Overweight and Obese People: Fractal Power Signatures beyond Two-Thirds or Three-FourthsHALL IL, Ronald G; SWANCUTT, Mark A; MEEK, Claudia et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 5, pp 2259-2264, issn 0066-4804, 6 p.Article